 Andrew Kwilasz
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuralgia | 8 | 2023 | 122 | 1.960 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 2 | 2021 | 50 | 1.430 |
Why?
| | Hyperalgesia | 5 | 2023 | 107 | 1.010 |
Why?
| | Multiple Sclerosis | 3 | 2021 | 380 | 0.990 |
Why?
| | Behavior, Animal | 5 | 2020 | 472 | 0.970 |
Why?
| | Toll-Like Receptor 4 | 3 | 2021 | 288 | 0.910 |
Why?
| | Toll-Like Receptor 2 | 2 | 2021 | 114 | 0.880 |
Why?
| | Naltrexone | 3 | 2020 | 82 | 0.880 |
Why?
| | Sciatic Neuropathy | 3 | 2022 | 24 | 0.880 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 138 | 0.810 |
Why?
| | Analgesics | 2 | 2014 | 157 | 0.790 |
Why?
| | Pain | 3 | 2021 | 712 | 0.720 |
Why?
| | Memory Disorders | 1 | 2020 | 155 | 0.680 |
Why?
| | Rats, Sprague-Dawley | 10 | 2022 | 2262 | 0.640 |
Why?
| | Sciatic Nerve | 1 | 2018 | 56 | 0.630 |
Why?
| | Phenethylamines | 1 | 2018 | 17 | 0.610 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2018 | 19 | 0.610 |
Why?
| | Pain Management | 1 | 2021 | 291 | 0.600 |
Why?
| | Interleukin-10 | 3 | 2023 | 304 | 0.600 |
Why?
| | Piperidines | 1 | 2018 | 163 | 0.580 |
Why?
| | Adenosine | 1 | 2018 | 204 | 0.540 |
Why?
| | Hippocampus | 1 | 2020 | 709 | 0.530 |
Why?
| | Rats | 10 | 2023 | 5035 | 0.530 |
Why?
| | Spinal Cord Injuries | 1 | 2018 | 174 | 0.490 |
Why?
| | Inflammation | 3 | 2020 | 2502 | 0.480 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 71 | 0.480 |
Why?
| | Amidohydrolases | 1 | 2014 | 29 | 0.470 |
Why?
| | Carbamates | 1 | 2014 | 35 | 0.460 |
Why?
| | Benzamides | 1 | 2014 | 169 | 0.440 |
Why?
| | Cyclohexanols | 1 | 2012 | 9 | 0.420 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2012 | 30 | 0.420 |
Why?
| | Osteoarthritis | 1 | 2014 | 173 | 0.410 |
Why?
| | Dronabinol | 1 | 2012 | 118 | 0.380 |
Why?
| | Parkinson Disease | 1 | 2014 | 325 | 0.370 |
Why?
| | Peripheral Nerve Injuries | 2 | 2022 | 32 | 0.360 |
Why?
| | Mecamylamine | 1 | 2009 | 8 | 0.340 |
Why?
| | Nicotinic Antagonists | 1 | 2009 | 20 | 0.340 |
Why?
| | Conditioning, Operant | 4 | 2019 | 99 | 0.330 |
Why?
| | Animals | 14 | 2023 | 32158 | 0.310 |
Why?
| | Nicotinic Agonists | 1 | 2009 | 101 | 0.310 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2009 | 159 | 0.290 |
Why?
| | Nicotine | 1 | 2009 | 267 | 0.280 |
Why?
| | Depression | 1 | 2014 | 1145 | 0.260 |
Why?
| | Male | 15 | 2023 | 56103 | 0.240 |
Why?
| | Interleukin-1beta | 2 | 2023 | 370 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 1871 | 0.220 |
Why?
| | Signal Transduction | 2 | 2019 | 4527 | 0.210 |
Why?
| | Chronic Pain | 2 | 2023 | 210 | 0.210 |
Why?
| | Inflammasomes | 1 | 2023 | 116 | 0.200 |
Why?
| | Spinal Cord | 2 | 2023 | 351 | 0.200 |
Why?
| | Microglia | 2 | 2020 | 205 | 0.200 |
Why?
| | Lactic Acid | 2 | 2014 | 276 | 0.200 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2021 | 43 | 0.190 |
Why?
| | Neuropeptide Y | 1 | 2019 | 13 | 0.180 |
Why?
| | Conditioning, Classical | 1 | 2020 | 86 | 0.180 |
Why?
| | Satiation | 1 | 2019 | 22 | 0.170 |
Why?
| | Food Deprivation | 1 | 2019 | 20 | 0.170 |
Why?
| | Time Perception | 1 | 2019 | 24 | 0.170 |
Why?
| | Discrimination Learning | 1 | 2019 | 47 | 0.170 |
Why?
| | Hunger | 1 | 2019 | 39 | 0.170 |
Why?
| | Lymphocyte Antigen 96 | 1 | 2019 | 24 | 0.170 |
Why?
| | Oxycodone | 1 | 2019 | 44 | 0.170 |
Why?
| | Fentanyl | 1 | 2019 | 66 | 0.170 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 8 | 0.160 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 23 | 0.160 |
Why?
| | Morphine | 1 | 2019 | 124 | 0.160 |
Why?
| | Injections, Spinal | 1 | 2018 | 102 | 0.160 |
Why?
| | Mice | 4 | 2021 | 15085 | 0.160 |
Why?
| | Fear | 1 | 2020 | 296 | 0.150 |
Why?
| | Cytokines | 3 | 2021 | 1858 | 0.140 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 4 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 223 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2020 | 3914 | 0.130 |
Why?
| | Analgesics, Opioid | 2 | 2019 | 783 | 0.130 |
Why?
| | Implantable Neurostimulators | 1 | 2014 | 5 | 0.120 |
Why?
| | Polyunsaturated Alkamides | 1 | 2014 | 8 | 0.120 |
Why?
| | Receptors, Cannabinoid | 1 | 2014 | 14 | 0.120 |
Why?
| | Feeding Behavior | 1 | 2019 | 574 | 0.120 |
Why?
| | Arachidonic Acids | 1 | 2014 | 58 | 0.120 |
Why?
| | Injections, Intraperitoneal | 1 | 2014 | 104 | 0.120 |
Why?
| | Endocannabinoids | 1 | 2014 | 37 | 0.110 |
Why?
| | Self Administration | 1 | 2014 | 124 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1758 | 0.110 |
Why?
| | Electric Stimulation | 1 | 2014 | 263 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1003 | 0.110 |
Why?
| | Self Stimulation | 1 | 2012 | 1 | 0.110 |
Why?
| | Ketoprofen | 1 | 2012 | 2 | 0.110 |
Why?
| | Electrodes, Implanted | 1 | 2012 | 92 | 0.100 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 301 | 0.100 |
Why?
| | Brain | 2 | 2014 | 2372 | 0.100 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 4779 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 758 | 0.090 |
Why?
| | Eating | 1 | 2012 | 349 | 0.090 |
Why?
| | Infusion Pumps, Implantable | 1 | 2009 | 20 | 0.090 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 19 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 301 | 0.090 |
Why?
| | Mice, Inbred ICR | 1 | 2009 | 111 | 0.080 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 145 | 0.080 |
Why?
| | Habituation, Psychophysiologic | 1 | 2009 | 55 | 0.080 |
Why?
| | Female | 5 | 2023 | 60070 | 0.070 |
Why?
| | Constriction | 1 | 2023 | 45 | 0.060 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 10 | 0.050 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 42 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 160 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 73 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2023 | 267 | 0.050 |
Why?
| | Superoxides | 1 | 2022 | 215 | 0.050 |
Why?
| | Chemokines | 1 | 2021 | 214 | 0.040 |
Why?
| | Stereoisomerism | 1 | 2019 | 91 | 0.040 |
Why?
| | Time Factors | 1 | 2009 | 6182 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2019 | 3587 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 327 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 534 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 511 | 0.040 |
Why?
| | Reward | 1 | 2019 | 208 | 0.040 |
Why?
| | Astrocytes | 1 | 2019 | 165 | 0.040 |
Why?
| | Pain Measurement | 1 | 2019 | 449 | 0.040 |
Why?
| | Motor Activity | 1 | 2022 | 635 | 0.040 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 4 | 0.040 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 4 | 0.040 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2016 | 13 | 0.040 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 14 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2023 | 1318 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2016 | 42 | 0.030 |
Why?
| | Nitrites | 1 | 2016 | 76 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1357 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2016 | 210 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 201 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2016 | 127 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 262 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 823 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2016 | 206 | 0.030 |
Why?
| | Humans | 4 | 2023 | 115859 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1137 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 503 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2657 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2019 | 1709 | 0.030 |
Why?
|
|
Kwilasz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|